Therapeutic vaccines for leishmaniasis

Bibliography

• Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7(5):e35671
   PubMed Web of Science ®Google Scholar
• Akilov OE, Khachemoune A, Hasan T. Clinical manifestations and classification of Old World cutaneous leishmaniasis. Int J Dermatol 2007;46(2):132-42
   PubMed Web of Science ®Google Scholar
• Gontijo B, de Carvalho Mde L. American cutaneous leishmaniasis. Rev Soc Bras Med Trop 2003;36(1):71-80
   PubMedGoogle Scholar
• Bonfante-Garrido R, Barroeta S, de Alejos MA, et al. Disseminated American cutaneous leishmaniasis. Int J Dermatol 1996;35(8):561-5
   PubMed Web of Science ®Google Scholar
• Das A, Ali N. Vaccine prospects of killed but metabolically active Leishmania against visceral leishmaniasis. Expert Rev Vaccines 2012;11(7):783-5
   PubMed Web of Science ®Google Scholar
• Goto H, Prianti M. Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 2009;51(5):241-6
   PubMed Web of Science ®Google Scholar
• Khalil EA, El Hassan AM, Zijlstra EE, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000;356(9241):1565-9
   PubMed Web of Science ®Google Scholar
• Nagill R, Kaur S. Vaccine candidates for leishmaniasis: a review. Int Immunopharmacol 2011;11(10):1464-88
   PubMed Web of Science ®Google Scholar
• WHO. Post-kala-azar dermal leishmaniasis: a manual for case management and control. report of a who consultative meeting. Kolkata, India;2012 Available from: http://apps.who.int/iris/bitstream/10665/78608/1/9789241505215_eng.pdf
   Google Scholar
• Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010;8(4):419-33
   PubMed Web of Science ®Google Scholar
• Barroso PA, Marco JD, Calvopina M, et al. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate. J Antimicrob Chemother 2007;59(6):1123-9
   PubMed Web of Science ®Google Scholar
• Croft SL, Olliaro P. Leishmaniasis chemotherapy-challenges and opportunities. Clin Microbiol Infect 2011;17(10):1478-83
   PubMed Web of Science ®Google Scholar
• Firooz A, Khamesipour A, Ghoorchi MH, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 2006;142(12):1575-9
   PubMed Web of Science ®Google Scholar
• Khatami A, Firooz A, Gorouhi F, et al. Systematic review of new world cutaneous leishmaniasis: several points. Int J Dermatol 2009;48(2):201; author reply 201-2
   PubMed Web of Science ®Google Scholar
• Bumb RA, Prasad N, Aara N, et al. Long-term efficacy of a single-dose Radio Frequency Heat therapy versus intralesional antimonials for cutaneous leishmaniasis in India. Br J Dermatol 2013;168(5):1114-19
   PubMed Web of Science ®Google Scholar
• Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002;2(11):845-58
   PubMed Web of Science ®Google Scholar
• Bogdan C. Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats. Ann Rheum Dis 2012;71(Suppl 2):i60-6
   PubMedGoogle Scholar
• Peters NC, Egen JG, Secundino N, et al. In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 2008;321(5891):970-4
   PubMed Web of Science ®Google Scholar
• Habibi GR, Khamesipour A, McMaster WR, et al. Cytokine gene expression in healing and non-healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi-quantitative RT-PCR. Scand J Immunol 2001;54(4):414-20
   PubMed Web of Science ®Google Scholar
• Hejazi SH, Hoseini S, Javanmard SH, et al. Interleukin-10 and transforming growth factor-beta in early and late lesions of patients with leishmania major induced cutaneous leishmaniasis. Iran J Parasitol 2012;7(3):16-23
   Web of Science ®Google Scholar
• Hoseini SG, Javanmard SH, Zarkesh SH, et al. Regulatory T-cell profile in early and late lesions of cutaneous leishmaniasis due to Leishmania major. J Res Med Sci 2012;17(6):513-18
   Web of Science ®Google Scholar
• Jafari-Shakib R, Ajdary S, Amiri ZM, et al. CD26 expression on CD4+T cells in patients with cutaneous leishmaniasis. Clin Exp Immunol 2008;153(1):31-6
   PubMed Web of Science ®Google Scholar
• Khamesipour A, Dowlati Y, Asilian A, et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005;23(28):3642-8
   PubMed Web of Science ®Google Scholar
• Mahmoodi M, Khamesipour A, Dowlati Y, et al. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clin Exp Immunol 2003;134(2):303-8
   PubMed Web of Science ®Google Scholar
• Nateghi Rostami M, Keshavarz H, Edalat R, et al. CD8+ T cells as a source of IFN-gamma production in human cutaneous leishmaniasis. PLoS Negl Trop Dis 2010;4(10):e845
   PubMedGoogle Scholar
• Tolouei S, Ghaedi K, Khamesipour A, et al. IL-23 and IL-27 levels in macrophages collected from peripheral blood of patients with healing vs non-healing form of cutaneous leishmaniasis. Iran J Parasitol 2012;7(1):18-25
   Web of Science ®Google Scholar
• Nateghi Rostami M, Keshavarz Valian H, Eskandari SE, et al. Differential in vitro CD4+/CD8+ T-cell response to live vs. killed Leishmania major. Parasite Immunol 2010;32(2):101-10
   PubMed Web of Science ®Google Scholar
• Noazin S, Khamesipour A, Moulton LH, et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 2009;27(35):4747-53
   PubMed Web of Science ®Google Scholar
• Duthie MS, Vanitha RS, Franco PM, et al. The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine 2012;30(2):134-41
   PubMed Web of Science ®Google Scholar
• Singh B, Sundar S. Leishmaniasis: vaccine candidates and perspectives. Vaccine 2012;30(26):3834-42
   PubMed Web of Science ®Google Scholar
• Badiee A, Jaafari MR, Samiei A, et al. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin Vaccine Immunol 2008;15(4):668-74
   PubMed Web of Science ®Google Scholar
• Firouzmand H, Badiee A, Khamesipour A, et al. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA). Acta Trop 2013;128(3):528-35
   PubMed Web of Science ®Google Scholar
• Momeni AZ, Jalayer T, Emamjomeh M, et al. A randomized, double blind, controlled trial of a killed L. major vaccine plus BCG against ZCL in Iran. Vaccine 1999;17:466-72
   PubMed Web of Science ®Google Scholar
• Sharifi I, Fekri A, Aflatonian M, et al. Double-blind randomized controlled vaccine trial of a single dose of killed Leishmania major plus Bacillus of Calmette Guerin (BCG) against anthroponotic cutaneous Leishmaniasis Bam, Iran. Lancet 1998
   PubMed Web of Science ®Google Scholar
• Alvar J, Croft SL, Kaye P, et al. Case study for a vaccine against leishmaniasis. Vaccine 2013;31(Suppl 2):B244-9
   PubMed Web of Science ®Google Scholar
• Badiee A, Heravi Shargh V, Khamesipour A, et al. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends. Vaccine 2013;31(5):735-49
   PubMed Web of Science ®Google Scholar
• Okwor I, Uzonna JE. As a strategy for treatment of leishmaniasis: a review of the literature. Immunotherapy 2009;1(5):765-76
   PubMed Web of Science ®Google Scholar
• Simon J. Emil Behring's medical culture: from disinfection to serotherapy. Med Hist 2007;51(2):201-18
   PubMed Web of Science ®Google Scholar
• Chakravarty J, Kumar S, Trivedi S, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 2011;29(19):3531-7
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003;9:269-77
   PubMed Web of Science ®Google Scholar
• Pennington JE. Immunotherapy of infectious diseases: past, present and future. Trans Am Clin Climatol Assoc 1988;99:126-35
   PubMedGoogle Scholar
• Luke TC, Arturo C, Stanley WJ, et al. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010;38:e66-73
   PubMed Web of Science ®Google Scholar
• Okwora I, Liua D, Beverley SM, et al. Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process. Proc Natl Acad Sci USA 2009;106(33):13951-6
   PubMed Web of Science ®Google Scholar
• Machado-Pinto J, Pinto J, da Costa CA, et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmanin amazonensis vaccine plus antimonial. Int J Dermatol 2002;41(2):73-8
   PubMed Web of Science ®Google Scholar
• Toledo VP, Mayrink W, Gollob KJ, et al. Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment. Mem Inst Oswaldo Cruz 2001;96(1):89-98
   PubMed Web of Science ®Google Scholar
• Mayrink W, Botelho AC, Magalhaes PA, et al. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop 2006;39(1):14-21
   PubMed Web of Science ®Google Scholar
• Convit J, Ulrich M, Zerpa O, et al. Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990–1999. Trans R Soc Trop Med Hyg 2003;97:469-72
   PubMed Web of Science ®Google Scholar
• Cabrera M, Blackwell JM, Castes M, et al. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol 2000;22(2):73-9
   PubMed Web of Science ®Google Scholar
• Convit J, Ulrich M, Polegre MA, et al. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem Inst Oswaldo Cruz 2004;99(1):57-62
   PubMed Web of Science ®Google Scholar
• O’Daly JA, Spinetti HM, Gleason J, et al. Clinical and immunological analysis of cutaneous leishmaniasis before and after different treatments. J Parasitol Res 2013;2013:657016
   PubMedGoogle Scholar
• Khalil EA, Musa AM, Modabber F, et al. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study. Ann Trop Paediatr 2006;26(4):357-61
   PubMed Web of Science ®Google Scholar
• Musa AM, Khalil EA, Mahgoub FA, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 2008;102(1):58-63
   PubMed Web of Science ®Google Scholar
• Modabber F. Leishmaniasis vaccines: past, present and future. PLoS Negl Trop Dis 2010;36(Suppl 1):S51-61
   Google Scholar
• Badaro R, Lobo I, Munos A, et al. Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis 2006;194(8):1151-9
   PubMed Web of Science ®Google Scholar
• Nascimento E, Fernandes DF, Vieira EP, et al. Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses. Infect Immun 1990;58(7):2198-203
   PubMed Web of Science ®Google Scholar
• Awasthi A, Mathur RK, Saha B. Immune response to Leishmania infection. Indian J Med Res 2004;119(6):238-58
   PubMed Web of Science ®Google Scholar
• Beattie L, Kaye PM. Leishmania-host interactions: what has imaging taught us? Cell Microbiol 2011;13(11):1659-67
   PubMed Web of Science ®Google Scholar
• Bogdan C. Natural killer cells in experimental and human leishmaniasis. Front Cell Infect Microbiol 2012;2:69
   Google Scholar
• De Almeida Silva L, Romero HD, Prata A, et al. Immunologic tests in patients after clinical cure of visceral leishmaniasis. Am J Trop Med Hyg 2006;75(4):739-43
   PubMed Web of Science ®Google Scholar
• Gaafar A, el Kadaro AY, Theander TG, et al. The pathology of cutaneous leishmaniasis due to Leishmania major in Sudan. Am J Trop Med Hyg 1995;52(5):438-42
   PubMed Web of Science ®Google Scholar
• Kaye PM, Aebischer T. Visceral leishmaniasis: immunology and prospects for a vaccine. Clin Microbiol Infect 2011;17(10):1462-70
   PubMed Web of Science ®Google Scholar
• Musa AM, Noazin S, Khalil EA, et al. Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration. Trans R Soc Trop Med Hyg 2010;104(1):1-2
   PubMed Web of Science ®Google Scholar
• Nylen S, Gautam S. Immunological perspectives of leishmaniasis. J Glob Infect Dis 2010;2(2):135-46
   PubMedGoogle Scholar
• Evans KJ, Kedzierski L. Development of vaccines against visceral leishmaniasis. J Trop Med 2012;2012:892817
   PubMedGoogle Scholar